PA
IMNM icon

Profund Advisors’s Immunome IMNM Stock Holding History

Profund Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53M Buy
69,918
+27,218
+64% +$606K 0.06% 245
2025
Q4 		$917K Buy
42,700
+23,440
+122% +$411K 0.03% 372
2025
Q3 		$226K Buy
19,260
+2,723
+16% +$27.1K 0.01% 907
2025
Q2 		$154K Sell
16,537
-5,064
-23% -$41.5K 0.01% 936
2025
Q1 		$145K Buy
21,601
+5,507
+34% +$52.8K 0.01% 933
2024
Q4 		$171K Sell
16,094
-1,453
-8% -$17.6K 0.01% 1034
2024
Q3 		$257K Sell
17,547
-4,082
-19% -$58K 0.01% 897
2024
Q2 		$262K Buy
+21,629
New +$338K 0.01% 809

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Profund Advisors's IMNM Position: Q1 2026 in Review

Profund Advisors increased its Immunome (IMNM) stake by 64% in Q1 2026, buying an estimated $606K and bringing the position to 69,918 shares worth $1.53M. The position accounts for 0.06% of the portfolio, ranked #245.

Profund Advisors first reported a position in IMNM in Q2 2024 and has held it in 8 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Profund Advisors held 69,918 shares of Immunome worth $1.53M as of Q1 2026.
  • Profund Advisors bought 27,218 Immunome shares in Q1 2026, an estimated $606K.
  • Immunome made up 0.06% of Profund Advisors's portfolio in Q1 2026, its #245 holding.
  • Profund Advisors first reported a position in Immunome in Q2 2024 and has held it in 8 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.